

WALDER WYSS ADVISES SWISSCANTO INVEST ON SERIES B FINANCING ROUND OF MEMO THERAPEUTICS

Posted on 11 November 2020



Category: [Deal & transactions](#)

Tags: [Alex Nikitine](#), [Dimitrios Berger](#), [Ex-Featured](#), [Hugh Reeves](#), [Judith Rothen](#), [Thiemo Sturny](#)



Walder Wyss has advised **Swisscanto Invest** in connection with its investment as lead investor in a CHF 14 mio. Series B Financing Round of **Memo Therapeutics**, an innovator in the field of antibody discovery and immune repertoire analysis. Proceeds from the financing round will be primarily used to advance development of MTX-COVAB, Memo Therapeutics' lead antibody candidate for the treatment of Covid-19, through to Phase II clinical studies.

The team

The Walder Wyss team has been led by Alex Nikitine (Partner, Corporate/M&A - pictured) and included Thiemo Sturny (Partner, Corporate/M&A), Dimitrios Berger (Associate, Corporate/M&A), Hugh Reeves (Senior Associate, IP/IT) and Judith Rothen (Trainee, Corporate/M&A).